Literature DB >> 32130023

Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease.

Mario Cazzola1, Francesco Cavalli1, Omar S Usmani2, Paola Rogliani1.   

Abstract

Introduction: Proper device selection is crucial for the clinical results of inhalation therapy. However, none of the available devices fully conforms to the requirements for delivering drug with increased patient adherence, and we are still looking for the ideal inhaler. For this reason, there are several ongoing technical innovations to improve inhaler devices.Areas covered: Progress in pulmonary drug delivery device technology is examined, focusing on innovations in pressurized metered dose inhalers, dry powder inhalers, nebulizers, and soft mist inhalers.Expert opinion: Both formulation improvements and new device technologies have been developed over the last couple of decades through an improved understanding of the mechanisms of aerosolization and lung deposition. Digital health is offering the potential to produce inhalers with a wider range of monitoring capabilities, but further studies are needed, in particular as regards the analysis of cost-effectiveness. Furthermore, there are still substantial issues that must be overcome in order to continually innovate and improve targeted inhaled drug delivery to the lungs. In any case, there are other potential therapeutic possibilities for COPD in development that may be administered by inhalation, whose clinical use requires advances and improvements in the devices used for administration.

Entities:  

Keywords:  COPD; add-on spacer devices; breath-actuated pMDI; dry powder inhaler; nebulizers; pressurized metered-dose inhaler; soft mist inhaler; technological innovations

Mesh:

Substances:

Year:  2020        PMID: 32130023     DOI: 10.1080/17425247.2020.1739021

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  7 in total

Review 1.  Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.

Authors:  Shohreh Alipour; Laleh Mahmoudi; Fatemeh Ahmadi
Journal:  Drug Deliv Transl Res       Date:  2022-10-19       Impact factor: 5.671

Review 2.  Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.

Authors:  Gokben Sahin; Ozlem Akbal-Dagistan; Meltem Culha; Aybige Erturk; Nur Sena Basarir; Serap Sancar; Ayca Yildiz-Pekoz
Journal:  J Pharm Sci       Date:  2022-06-09       Impact factor: 3.784

Review 3.  The future of inhalation therapy in chronic obstructive pulmonary disease.

Authors:  Mario Cazzola; Josuel Ora; Luigino Calzetta; Paola Rogliani; Maria Gabriella Matera
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-02-17

Review 4.  Concepts of advanced therapeutic delivery systems for the management of remodeling and inflammation in airway diseases.

Authors:  Daljeet Singh Dhanjal; Parvarish Sharma; Meenu Mehta; Murtaza M Tambuwala; Parteek Prasher; Keshav R Paudel; Gang Liu; Shakti D Shukla; Philip M Hansbro; Dinesh Kumar Chellappan; Kamal Dua; Saurabh Satija
Journal:  Future Med Chem       Date:  2022-01-12       Impact factor: 3.808

Review 5.  The Current and Future Role of Technology in Respiratory Care.

Authors:  Persijn Honkoop; Omar Usmani; Matteo Bonini
Journal:  Pulm Ther       Date:  2022-04-26

6.  Stability and In Vitro Aerodynamic Studies of Inhalation Powders Containing Ciprofloxacin Hydrochloride Applying Different DPI Capsule Types.

Authors:  Edit Benke; Patrícia Varga; Piroska Szabó-Révész; Rita Ambrus
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321

7.  Editorial overview: Respiratory: Pulmonary pharmacology-The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives.

Authors:  Mario Cazzola; Maria Gabriella Matera; Luigino Calzetta; Paola Rogliani
Journal:  Curr Opin Pharmacol       Date:  2021-08-02       Impact factor: 5.547

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.